Glycoproteins GPVI and GPIb-IX-V stimulate robust tyrosine phosphorylation of Syk and PLCγ 2 (phospholipase Cγ 2) in washed platelets, but only the former stimulates pronounced activation of phospholipase. Using phospho-specific antibodies, we demonstrate that GPVI, but not GPIb-IX-V, stimulates significant tyrosine phosphorylation of Syk at the autophosphorylation site pY525/526, a marker of Syk activity. 
INTRODUCTION
PLCγ 2 (phospholipase Cγ 2) is the major PLCγ isoform expressed in platelets [1] . It is activated by the collagen receptor glycoprotein (GP) VI, which associates with the Fc receptor γ -chain. The Fc receptor γ -chain contains one copy of an ITAM (immunoreceptor tyrosine-based activation motif) in its cytoplasmic tail. PLCγ 2 is also activated by platelet integrins αIIbβ3 and α2β1 through a pathway, which is independent of an ITAM [2] [3] [4] . Stimulation of PLCγ 2 by GPVI and integrin receptors is mediated downstream of the tyrosine kinase Syk through a pathway that involves the adapter SLP-76 (SH2-containing leucocyte phosphoprotein of 76 kDa) [5] , although the two signalling cascades are distinct and are believed to take place in distinct regions of the membrane [6] . Syk, SLP-76 and PLCγ 2 have been shown to play a critical role in platelet activation by GPVI and integrin receptors [2] [3] [4] 7, 8] .
vWF (von Willebrand factor) is a multimeric protein, which mediates platelet tethering to the exposed subendothelium at sites of arteriole injury via the GPIb-IX-V complex. In addition, GPIb generates intracellular signals that lead to weak activation of integrin αIIbβ3. Similar to GPVI and platelet integrins, GPIb-IX-V signals through an Src kinase-dependent pathway that involves tyrosine phosphorylation of Syk, SLP-76 and PLCγ 2 [9] [10] [11] [12] [13] . Although GPIb-IX-V stimulates robust tyrosine phosphorylation of PLCγ 2, it only stimulates, at best, weak activation of phospholipase, which is in marked contrast with the robust activation Abbreviations used: GP, glycoprotein; ITAM, immunoreceptor tyrosine-based activation motif; mAb, monoclonal antibody; pAb, polyclonal antibody; PLCγ2, phospholipase Cγ2; SLP-76, SH2-containing leucocyte phosphoprotein of 76 kDa; vWF, von Willebrand factor. 1 To whom correspondence should be addressed. Present address: Clinical and Laboratory Medicine, Faculty of Medicine, University of Yamanashi, Shimokato, Tamaho, Nakakoma, Yamanashi 409-3898, Japan (e-mail katsuei@yamanashi.ac.jp). 2 Present address: Pathway Discovery, Genomic and Proteomic Sciences, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, U.K. 3 Present address: Ahringer Laboratory, Wellcome/CR U.K. Institute, Tennis Court Road, Cambridge CB2 1QR, U.K.
induced by GPVI and the integrin αIIbβ3 (cf. e.g. [10, 11] with [12] ).
In the present study, we investigated the molecular basis of the discrepancy between the degree of tyrosine phosphorylation of PLCγ 2 by GPVI and GPIb-IX-V and the level of activation of phospholipase. To examine this, we mapped the phosphorylation sites of PLCγ 2 and the upstream tyrosine kinases Syk and Btk, using phospho-specific antibodies. Our results demonstrate fundamental differences in the sites of tyrosine phosphorylation of Syk and PLCγ 2 between GPVI and GPIb-IX-V, which explains the discrepancy in the magnitude of activation between the two receptors.
EXPERIMENTAL

Antibodies and reagents
Human vWF and botrocetin were donated by Dr M. C. Berndt (Monash University, Melbourne, Vic., Australia). Convulxin was a gift from Dr M. Leduc and Dr C. Bon (Institut Pasteur, Paris, France). Anti-PLCγ 2 pAb (polyclonal antibody) and anti-Btk pAb were gifts from Dr M. Tomlinson (DNAX, Palo Alto, CA, U.S.A.). The cDNA for human wild-type PLCγ 2 was subcloned into pcDNA3.1 plasmid (myc/his-tagged; Invitrogen, San Diego, CA, U.S.A.). Lotrafiban was a gift from GlaxoSmithKline (King of Prussia, PA, U.S.A.). Mutant PLCγ 2, in which Tyr 759 is replaced by a phenylalanine residue, was generated using the Quik Change site-directed mutagenesis kit (Stratagene, La Jolla, CA, U.S.A.) according to the manufacturer's instructions. The mutation was verified by sequencing. Anti-phosphotyrosine mAb (monoclonal antibody) 4G10 was purchased from Upstate Biotechnology (TCS Biological, Botolph Claydon, Bucks., U.K. 
Cell culture, transient transfection and stimulation of COS-7 cells
Cell culture and transient transfection of COS-7 cells using the calcium chloride method were performed as described previously [15] . Cells were detached by adding trypsin EDTA and incubating for 5 min at 37
• C. After washing with modified Tyrodes buffer (137 mM NaCl/11.9 mM NaHCO 3 /0.4 mM Na 2 HPO 4 /2.7 mM KCl/1.1 mM MgCl 2 /5.6 mM glucose, pH 7.3), they were stimulated by 4 mM H 2 O 2 and 1 mM vanadate for 10 min at 30
• C, followed by immunoprecipitation as described below.
Preparation and stimulation of platelets
Platelets were obtained from drug-free volunteers on the day of the experiment and suspended in modified Tyrodes buffer. They were washed as described previously [16] . Washed human platelets (5 × 10 8 /ml, 0.5 ml) were pretreated with integrin αIIbβ3 antagonist, 10 µM lotrafiban, 10 µM indomethacin and 3 units/ ml apyrase, followed by stimulation with 10 µg/ml convulxin or 10 µg/ml vWF plus 1 mg/ml ristocetin for the indicated time at 37
• C.
Immunoprecipitation
Stimulations were terminated by the addition of an equal volume of ice-cold lysis buffer [2 % (v/v) Nonidet P40, 20 mM Tris, 300 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1 mM PMSF, 2 mM Na 3 VO 4 , 10 µg/ml leupeptin, 10 µg/ml aprotinin and 1 µg/ml pepstatin A, pH 7.3]. Detergent-insoluble debris was removed by centrifugation at 15 000 g for 10 min and the supernatant precleared with Protein A-Sepharose [50 % (w/v) in Tris-buffered saline (TBS) plus Tween 20 (TBS-T; 20 mM Tris/137 mM NaCl/ 0.1 % (v/v) Tween 20, pH 7.6)] for 1 h at 4 • C. Specific antibodies and Protein A-Sepharose were added and each sample rotated at 4
• C overnight. Control samples were also set up alongside using isotype-matched antibodies or preimmune serum to demonstrate specificity. The Sepharose pellet was washed sequentially in lysis buffer and TBS-T, before addition of Laemmli sample buffer.
Immunoblotting
Proteins were separated by SDS/PAGE (8 % gels), electrotransferred and blotted as described previously [16] .
In vitro kinase assay
Syk and Btk were immunoprecipitated from stimulated or nonstimulated platelets as described above. After washing, the Protein A pellet was washed once in kinase wash buffer (105 mM NaCl/ 20 mM Hepes/5 mM MnCl 2 /5 mM MgCl 2 /100 µM vanadate). Kinase assay buffer (40 µl; kinase wash buffer plus 10 µM ATP, 0.5 µCi [
32 P]ATP and 50 µM substrate peptide
− ) was then added to the pellet. Samples were incubated at 37
• C for 10 min, mixing every 2 min, and then spun at 13 000 g for 2 min. Each sample (30 µl) was then applied to squares of p81 chromatography paper (which bind the peptides via a chargecharge interaction). Each p81 sample was air-dried for 30 s before 3 × 5 min washes in orthophosphoric acid solution and 3 × 5 min washes in acetone, before being allowed to dry overnight. The dried pieces of p81 were then placed in scintillation vials and subjected to a 5 min 32 P count. Each assay was performed in duplicate.
Preparation of murine platelets
PLCγ 2-deficient mice and integrin αIIb-deficient mice were used as described previously [2, 7] . Both sets of mice were bred from heterozygotes on a B6 background and genotyped by PCR as described in [8] . Wild-type littermates were used as controls. Murine blood was drawn from CO 2 terminally-anaesthetized mice by cardiac puncture and taken into 100 µl of ACD (aged citric acid/sodium citrate/dextrose) and washed platelets were prepared as described previously [17] . Murine platelets were resuspended in modified Tyrodes buffer at a cell density of 2 × 10 8 /ml. Washed murine platelets were pretreated with vehicle solution or 10 µM lotrafiban for 5 min before stimulation with 5 µg/ml botrocetin in the presence of 10 µg/ml human vWF. Platelet aggregation was monitored using BioData PAP-4 (Alpha Laboratories, Eastleigh, Hants, U.K.).
Statistical evaluation
Statistical analysis was performed using the unpaired Student's t test with P < 0.05 taken as significant.
RESULTS
Distinct sites of tyrosine phosphorylation of PLCγ 2 by GPIb and GPVI
The GPVI-specific snake toxin convulxin induces powerful tyrosine phosphorylation and activation of PLCγ 2 in platelets [18] . In contrast, despite marked tyrosine phosphorylation of PLCγ 2, ristocetin/vWF induces minimal activation of phospholipase [10] [11] [12] . To investigate whether this discrepancy is due to differences in the sites of phosphorylation of PLCγ 2 by the two GP receptors, we raised phospho-specific antibodies to the two major regulatory sites Tyr 753 and Tyr 759 [19, 20] . (Figure 1 ). Several minor bands were seen after longer exposures, but did not change after activation. The same approach was used to recognize an antibody to Tyr 753 . A full report of the characteristics of this antibody will be reported elsewhere (Y. J. Kim, F. Sekiya and S. G. Rhee, unpublished work).
As previously reported, the GPVI-specific snake toxin convulxin stimulates rapid and robust tyrosine phosphorylation of PLCγ 2 which peaks within 15 s and decreases slightly after 5 min (Figure 2A ). Ristocetin/vWF also stimulated robust tyrosine phosphorylation of PLCγ 2 within 15 s, although this increased further by 5 min (Figure 2A) . Interestingly, both convulxin and vWF-ristocetin stimulated marked phosphorylation of Tyr 753 , whereas only convulxin induced significant phosphorylation of Tyr 759 when measured at the time of peak tyrosine phosphorylation of PLCγ 2 for each stimulus ( Figure 2B ). Similar results were also seen at other times (results not shown). The absence of detectable tyrosine phosphorylation of Tyr 759 provides a molecular explanation for the relatively weak activation of PLCγ 2 by vWFristocetin.
vWF-ristocetin does not induce detectable tyrosine phosphorylation of Syk at the autophosphorylation site
Studies in Syk-deficient mouse platelets have demonstrated a key role for the kinase in the regulation of PLCγ 2 by GPVI [21] . Syk is phosphorylated on multiple sites downstream of ITAM-coupled receptors [22] . Of these, autophosphorylation of in the activation loop of Syk is essential for full activation and can be used as a marker of activity [14] . In addition, phosphorylation of Tyr 352 has been shown to mediate association of Syk with PLCγ 1 [23] . We used phospho-specific antibodies to these two sites to investigate their phosphorylation downstream of GPVI and GPIb-IX-V. (1) + H 3 N-ERDINSLYDVSRMYVDPSE-CO 2 − , (2) + H 3 N-ERDINSLFDVSRMY-VDPSE-CO 2 − and (3) + H 3 N-ERDINSLYDVSRMFVDPSE-CO 2 − ]. The samples were incubated at 37 • C for 10 min and then spun at 13 000 g for 2 min. Each sample (30 µl) was applied to squares of p81 chromatography paper, washed, and dried overnight as described in the Experimental section. The dried pieces of p81 were then analysed by scintillation counting. Each assay was performed in duplicate.
identifies Syk as a candidate kinase for mediating phosphorylation of Tyr 759 . Additionally, the ability of convulxin and vWFristocetin to induce activation of Btk and phosphorylation of Tyr 753 in PLCγ 2 suggests that the Tec family may mediate phosphorylation of phospholipase at this site.
To explore this in further detail, we performed in vitro kinase assays on Btk and Syk immunoprecipitates using peptides from the PLCγ 2 linker region that contained Tyr 753 and/or Tyr 759 ( Figure 4A ). Immunoprecipitates of Btk and Syk promoted incorporation of 32 P into a peptide containing Tyr 753 and Tyr
759
( Figures 4B and 4C) . Interestingly, Syk immunoprecipitate from basal and convulxin-stimulated platelets induced a similar level of phosphorylation of the peptide, whereas Btk immunoprecipitate from stimulated platelets induced a greater level of phosphorylation ( Figures 4B and 4C) . The absence of an increase in phosphorylation by Syk is consistent with our previous observation that autophosphorylation of the kinase is also similar in kinase assays performed in vitro on basal and stimulated platelets. This suggests that autophosphorylation, which regulates the kinase activity of Syk, is not rate-limiting in these experiments.
To investigate the specificity of phosphorylation by Syk and Btk, we designed two more peptides in which Tyr  753 and Tyr   759 were replaced by a Phe residue. Interestingly, the peptide containing Tyr 759 and Phe 753 was phosphorylated only by Syk, whereas the converse was the case for the peptide containing Tyr 753 and Phe 759 , with phosphorylation being induced only by Btk (Figures 4B and 4C) . Btk also induced a much greater level of tyrosine phosphorylation of the peptide containing Phe 759 demonstrating that phosphorylation of Tyr 753 is modulated by the presence of tyrosine or phenylalanine at position 759 ( Figure 4C) 
PLCγ 2 does not play a role in aggregation induced by vWF-ristocetin
We used murine platelets to investigate the functional role of PLCγ 2 in GPIb-dependent activation of integrin αIIbβ3. We used botrocetin/vWF in these studies because ristocetin/vWF is not effective in murine platelets. Botracetin/vWF promoted a slow increase in light transmission that was partially inhibited in the presence of the αIIbβ3 receptor antagonist, lotrafiban (Figures 5A and 5C ), indicating that it is made up of GPIb-dependent agglutination (which is insensitive to lotrafiban) and αIIbβ3-dependent aggregation. This was confirmed by the demonstration that lotrafiban had no effect on the increase in light transmission induced by botracetin/vWF in murine platelets deficient in αIIb (results not shown). Interestingly, however, lotrafiban caused a similar degree of inhibition of the increase in light transmission in PLCγ 2-deficient platelets induced by vWF/botrocetin to that seen in controls ( Figures 5B and 5C ), demonstrating that activation of αIIbβ3 is not dependent on PLCγ 2.
DISCUSSION
In the present study, we have investigated the discrepancy between the extent of tyrosine phosphorylation of PLCγ 2 by GPVI and GPIb-IX-V and the degree of activation of phospholipase [10, 11] . We demonstrate that this is due to distinct profiles of tyrosine phosphorylation of PLCγ 2 by the two receptors. GPVI stimulates tyrosine phosphorylation at the regulatory Tyr 753 and Tyr 759 in PLCγ 2, whereas GPIb-IX-V induces significant tyrosine phosphorylation of phospholipase at position 753. These observations are explained by a differential regulation of the upstream regulator Syk, with only GPVI inducing a significant tyrosine phosphorylation at its autophosphorylation site.
In the light of these results, it is interesting that both receptors stimulate a similar degree of tyrosine phosphorylation of the Tec family kinase, Btk, at its two regulatory sites. This demonstrates that tyrosine phosphorylation of Btk by GPIb-IX-V is mediated through a pathway distinct from that involved in the regulation of PLCγ 2. Additionally, these results raise the possibility that tyrosine phosphorylation of PLCγ 2 at positions 753 and 759 is mediated via Btk and Syk respectively. This is supported in the present study by phosphorylation studies using peptides from the linker region of PLCγ 2 and also by the report that a Y753F substitution in the PLCγ 2 fragment, PLCγ 2-639-770, markedly reduces phosphorylation by Btk in vitro [20] . Interestingly, the results also show that phosphorylation of Tyr 759 inhibits phosphorylation of Tyr 753 by Btk, demonstrating that the chronology of phosphorylation of these two sites in stimulated platelets influences the activation of PLCγ 2.
The distinct profile of tyrosine phosphorylation of Syk and PLCγ 2 by GPIb-IX-V relative to that induced by GPVI may be explained by our previous observation that the vWF receptor is excluded from cholesterol-rich lipid-rich domains, known as rafts, which play an essential role in signalling by GPVI [6] . Activation of PLCγ 2 by GPVI is critically dependent on tyrosine phosphorylation of the raft-associated membrane adapter LAT (linker for activation of T-cells), whereas the adapter is only minimally phosphorylated in response to activation of GPIb-IX-V. Further, GPVI signals via the related Src family kinases, Fyn and Lyn, which are located in these membrane domains [6, 27] , whereas GPIb-IX-V signals via the tyrosine kinase Src, which is located outside of membrane rafts [28] . Therefore GPIb-IX-V stimulates assembly of a unique signalling complex similar to that used by GPVI, which leads to tyrosine phosphorylation of Syk and PLCγ 2 at distinct sites.
A recent study has reported that up to 15 % of GPIb-IX-V may be associated with membrane rafts [29] . This probably reflects methodological differences with our own study, bearing in mind that there is no established way to isolate membrane rafts. Both studies, however, agree that the major portion of GPIb-IX-V lies outside of membrane rafts [6] . It is interesting to consider whether the small proportion of membrane-raft-associated GPIb-IX-V is able to signal in the same way as GPVI. This scenario may explain, e.g. a recent study [12] , which demonstrates a partial role for PLCγ 2 in mediating the weak increase in intracellular Ca 2+ that is induced by GPIb-IX-V engagement in murine platelets. Thus, we speculate that the minor pool of raft-associated GPIb-IX-V is capable of activating PLCγ 2 in a way similar to GPVI, whereas the much larger pool of non-raft-associated receptors stimulates tyrosine phosphorylation of phospholipase through a distinct signalling cascade. Our inability to detect tyrosine phosphorylation of Syk and PLCγ 2 by GPIb-IX-V at key regulatory sites, in the present study, by the raft-associated pool may reflect the limitations in sensitivity of the available phospho-specific antibodies and the weak nature of the signal.
In conclusion, we have shown that the discrepancy between the level of tyrosine phosphorylation of PLCγ 2 and the degree of activation between GPIb-IX-V and GPVI can be explained by differences in the extent of phosphorylation of key regulatory sites in Syk and PLCγ 2. This demonstrates the need for caution in equating tyrosine phosphorylation as measured using a pan phosphotyrosine antibody with function, most notably for receptors that signal through distinct signalling cascades.
